Want to see APRE full AI Analyst Report?
Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.50
▼(-47.58% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance (zero revenue, ongoing losses, and continued cash burn), reinforced by a technically weak downtrend (price below key moving averages). Offsetting factors include a debt-free balance sheet and moderately positive corporate developments (pipeline progress and expanded IP), but valuation is difficult to support given negative earnings and no dividend.
Positive Factors
Intellectual Property
A broad and potentially long-lived patent estate can protect Aprea’s precision-oncology assets from direct competition and preserve strategic partnering leverage. If clinical programs succeed, extended exclusivity could support commercialization economics over multiple years.
Negative Factors
No Recurring Revenue
The absence of recurring product revenue leaves Aprea without a demonstrated commercial engine to offset research and development costs. Until a program is approved and monetized, financial performance will remain tied to clinical progress and the availability of external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Intellectual Property
A broad and potentially long-lived patent estate can protect Aprea’s precision-oncology assets from direct competition and preserve strategic partnering leverage. If clinical programs succeed, extended exclusivity could support commercialization economics over multiple years.
Read all positive factors
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.46M
Dividend YieldN/A
Average Volume (3M)223.59K
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth-99.38%
EPS Growth53.42%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.08
Shares Outstanding12,591,136
10 Day Avg. Volume141,725
30 Day Avg. Volume223,588
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-442.84
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$3.30Price Target Upside247.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Aprea Therapeutics Business Overview & Revenue Model
Company Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The comp...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Aprea Therapeutics has historically not generated meaningful recurring revenue from product sales; its business model has primarily relied on financing to fund research and development. The company’s ...
Aprea Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | -5.43K | 0.00 | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -12.29M | -12.58M | -12.94M | -14.28M | -37.19M | -36.86M |
| Net Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | ||||||
| Total Assets | 42.29M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 3.82M | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 38.47M | 12.44M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | ||||||
| Free Cash Flow | -12.18M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.17M | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | -15.75K | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 36.89M | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Negative
0.95
Price Trends
0.71
Negative
0.70
Negative
0.76
Negative
Market Momentum
-0.06
Positive
37.42
Neutral
23.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Negative. The current price of 0.95 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.71, and above the 200-day MA of 0.76, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 23.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APRE.
Aprea Therapeutics Risk Analysis
Aprea Therapeutics disclosed 78 risk factors in its most recent earnings report. Aprea Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aprea Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $8.13M | -0.27 | -304.87% | ― | ― | 98.98% | |
44 Neutral | $6.46M | -0.48 | -46.72% | ― | -99.38% | 53.42% | |
44 Neutral | $4.74M | -0.28 | -41.95% | ― | ― | 99.50% | |
42 Neutral | $9.46M | -0.51 | -91.18% | ― | ― | 81.87% |
* Healthcare Sector Average
APRE
Aprea Therapeutics
0.51
-0.94
-64.62%
ERNA
Eterna Therapeutics
1.99
-42.01
-95.47%
QNRX
Quoin Pharmaceuticals
4.05
-8.25
-67.07%
NCNA
Nucana
1.10
-2.85
-72.15%
INAB
IN8bio
0.96
-1.04
-52.00%
Aprea Therapeutics Corporate Events
Business Operations and Strategy
Aprea Therapeutics Expands Global IP for Precision Oncology
Positive
Aug 28, 2026
On August 28, 2026, Aprea Therapeutics announced it had significantly expanded its global intellectual property portfolio supporting its precision oncology programs. The company now has 28 issued and 30 pending patents across its lead platforms, r...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Positive
Aug 12, 2026
On August 12, 2026, Aprea Therapeutics reported second-quarter 2026 results and detailed progress across its oncology pipeline, led by WEE1 inhibitor APR-1051. The company is accelerating enrollment in the ACESOT-1051 Phase 1 trial, expanding from...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.